Just about a year ago, Blueprint Medicines raised $169 million in Massachusetts' largest biotech IPO. Today, it's got three drugs in clinical trials - and, with a well-padded bank account, has time for a little whimsy.
Also, Blueprint Medicines Corp. partnered with Roche to discover, develop and commercialize up to five small molecules targeting undisclosed kinases.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Blueprint Medicines recently announced a $50 million Series C round, meant to advance its two lead candidates through clinical trials in 2015 and fund the company’s proprietary kinase discovery platform and pipeline. The round was led by Partner Fund Management; the company, launched by Third Rock Ventures, to this point has raised an impressive $115 […]